Clinical Research Directory
Browse clinical research sites, groups, and studies.
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
Sponsor: University of Washington
Summary
The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.
Key Details
Gender
FEMALE
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-08-13
Completion Date
2025-05-27
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
Doxycycline
Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
Locations (1)
Kenya Medical Research Institute -KEMRI
Kisumu, Kenya